Research Topics
Genomes and GenesSpecies | P J BarterSummaryAffiliation: The Heart Research Institute Country: Australia Publications
| Collaborators
|
Detail Information
Publications
Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panelP J Barter
Heart Research Institute, Camperdown, Sydney, NSW, Australia
J Intern Med 259:247-58. 2006..The evidence also indicates that the apo B/apo A-I ratio is superior to any of the conventional cholesterol ratios in patients without symptomatic vascular disease or diabetes to evaluate the lipoprotein-related risk of vascular disease...
Relationship between atorvastatin dose and the harm caused by torcetrapibPhilip J Barter
The Heart Research Institute, Sydney, Australia
J Lipid Res 53:2436-42. 2012..The harm could not be explained by torcetrapib-induced changes in lipid levels, blood pressure, or electrolytes. It is conceivable that higher doses of atorvastatin protected against the harm caused by torcetrapib...- The apolipoprotein A-I mimetic peptide, ETC-642, reduces chronic vascular inflammation in the rabbitBelinda A Di Bartolo
Lipid Research Group, Heart Research Institute, 7 Eliza St, Newtown, NSW 2042, Australia
Lipids Health Dis 10:224. 2011.... 
Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: Where are we now?Philip Barter
The Heart Research Institute, 7 Eliza Street, Newtown, Sydney 2042, Australia
Trends Pharmacol Sci 32:694-9. 2011..Clinical outcome trials with dalcetrapib and anacetrapib are currently under way...- The rationale for using apoA-I as a clinical marker of cardiovascular riskP J Barter
The Heart Research Institute, Sydney, Australia
J Intern Med 259:447-54. 2006..The fact that the main apolipoprotein of HDLs, apoA-I, plays a prominent role in each of these functions adds support to the view that apoA-I should be measured as a component of the assessment of cardiovascular risk in humans... - Are we lowering LDL cholesterol sufficiently?Philip Barter
The Heart Research Institute, Sydney, NSW, Australia
Nat Clin Pract Cardiovasc Med 3:290-1. 2006 - Relationship between the concentration and antiatherogenic activity of high-density lipoproteinsPhilip J Barter
The Heart Research Institute, Sydney, Australia
Curr Opin Lipidol 17:399-403. 2006..The relationship between the concentration of high-density lipoprotein cholesterol and their protective function is addressed... - Is it appropriate to make statins available over the counter? The argument against the appropriateness of over-the-counter statinsPhilip J Barter
The Heart Research Institute and the Department of Medicine, University of Sydney, Australia
Circulation 114:1315-20; discussion 1320. 2006 - Serum insulin and inflammatory markers in overweight individuals with and without dyslipidemiaPhilip Barter
The Heart Research Institute, Camperdown, New South Wales, Australia
J Clin Endocrinol Metab 92:2041-5. 2007..The worldwide epidemic of overweight and obesity is setting the scene for a new wave of premature cardiovascular disease... - Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome?Philip J Barter
The Heart Research Institute, Sydney, Australia 2050
Arterioscler Thromb Vasc Biol 28:39-46. 2008..It remains to be determined whether the combination of a fibrate plus statin reduces the risk beyond that achieved with a statin alone... - HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular eventsPhilip Barter
Heart Research Institute, Sydney, Australia
N Engl J Med 357:1301-10. 2007..High-density lipoprotein (HDL) cholesterol levels are a strong inverse predictor of cardiovascular events. However, it is not clear whether this association is maintained at very low levels of low-density lipoprotein (LDL) cholesterol... - Effects of torcetrapib in patients at high risk for coronary eventsPhilip J Barter
Heart Research Institute, Camperdown, Sydney, NSW, Australia
N Engl J Med 357:2109-22. 2007..We investigated whether torcetrapib, a potent CETP inhibitor, might reduce major cardiovascular events. The trial was terminated prematurely because of an increased risk of death and cardiac events in patients receiving torcetrapib... - New insights into the role of HDL as an anti-inflammatory agent in the prevention of cardiovascular diseasePhilip J Barter
The Heart Research Institute, 114 Pyrmont Bridge Road, Camperdown, Sydney 2050, Australia
Curr Cardiol Rep 9:493-8. 2007..These results have potentially important clinical implications in regard to managing the acute vascular inflammation states that accompany acute coronary syndrome and acute ischemic stroke... - Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER DatabasePhilip J Barter
Heart Research Institute, Sydney, Australia
J Lipid Res 51:1546-53. 2010..The HDL-C increase achieved by all three statins was independent of LDL-C decrease. However, baseline HDL-C and TGs and the presence of diabetes were predictors of statin-induced increases in HDL-C... - Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trialPhilip J Barter
The Heart Research Institute, Sydney, Australia
Circulation 124:555-62. 2011..We now investigate effects on glucose homeostasis of inhibiting cholesteryl ester transfer protein with torcetrapib... - HDL-C: role as a risk modifierPhilip Barter
The Heart Research Institute, 7 Eliza Street, Newtown, Sydney, NSW 2050, Australia
Atheroscler Suppl 12:267-70. 2011..Thus, there is a compelling case for targeting both the LDL and HDL fractions to reduce CV risk in people with dyslipidemia, high CV risk and low levels of HDL-C... - Raising HDL-C can be achieved by both lifestyle changes and pharmacological means. IntroductionPhilip Barter
The Heart Research Institute, 7 Eliza Street, Newtown, Sydney, NSW 2050, Australia
Atheroscler Suppl 12:265-6. 2011..This supplement will discuss the contribution of HDL-C as a possible predictor and modifiable risk factor for CV disease and will examine the potential role for pitavastatin in reducing residual CV risk... - Aggressive management of obesity in children and young adults: the known challenges and potential opportunitiesP J Barter
The Heart Research Institute, Sydney, Australia
Clin Pharmacol Ther 81:627-30. 2007..The world is confronted with an impending epidemic of premature cardiovascular disease (CVD) that is being fueled by an increase in the prevalence of central obesity... - Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trialPhilip Barter
The Heart Research Institute, 7 Eliza Street, Newtown, Sydney, New South Wales, Australia 2042
Am J Cardiol 104:10E-5E. 2009..The potential of CETP inhibition to reduce cardiovascular risk will be determined by the outcome of ongoing clinical trials with CETP inhibitors that do not share the off-target effects of torcetrapib... - Effects of cross-link breakers, glycation inhibitors and insulin sensitisers on HDL function and the non-enzymatic glycation of apolipoprotein A-IE Nobecourt
Lipid Research Group, The Heart Research Institute, 145 Missenden Road, Camperdown, Sydney, NSW 2050, Australia
Diabetologia 51:1008-17. 2008.... - The inflammation: lipoprotein cyclePhilip Barter
The Heart Research Institute, 145 Missenden Road, Camperdown, Sydney, NSW 2050, Australia
Atheroscler Suppl 6:15-20. 2005..Additional protection from atherosclerosis may be provided by novel therapies that aim to increase plasma levels and activity of HDLs... - Metabolic abnormalities: high-density lipoproteinsPhilip Barter
The Heart Research Institute, 145 Missenden Road, Camperdown, Sydney NSW 2050, Australia
Endocrinol Metab Clin North Am 33:393-403. 2004..The consequences of a low HDL concentration in this syndrome are addressed before the article concludes with a discussion of whether low HDL in the metabolic syndrome should be a therapeutic target... - Managing diabetic dyslipidaemia--beyond LDL-C:HDL-C and triglyceridesPhilip Barter
The Heart Research Institute, 145 Missenden Road, Camperdown, Sydney, NSW 2050, Australia
Atheroscler Suppl 7:17-21. 2006.... - HDL: a recipe for longevityPhilip Barter
The Heart Research Institute, 145 Missenden Road, Camperdown, Sydney, NSW 2050, Australia
Atheroscler Suppl 5:25-31. 2004..As data accumulate on the protective role of HDLs, there is growing support for interventions that act to raise HDL-C concentrations... - The impact of glycation on apolipoprotein A-I structure and its ability to activate lecithin:cholesterol acyltransferaseE Nobecourt
Lipid Research Group, The Heart Research Institute, 145 Missenden Road, Camperdown, Sydney, NSW, 2050, Australia
Diabetologia 50:643-53. 2007..The aim of this study was to determine how glycation affects the structure of apoA-I and its ability to activate lecithin:cholesterol acyltransferase (LCAT), a key enzyme in reverse cholesterol transport... - Role of 3beta-hydroxysteroid-delta 24 reductase in mediating antiinflammatory effects of high-density lipoproteins in endothelial cellsK C Y McGrath
Heart Research Institute, 114 Pyrmont Bridge Road, Camperdown, NSW, 2050, Australia
Arterioscler Thromb Vasc Biol 29:877-82. 2009..The purpose of this study was to investigate the ability of high-density lipoproteins (HDLs) to upregulate genes with the potential to protect against inflammation in endothelial cells... - Effectiveness of combined statin plus omega-3 fatty acid therapy for mixed dyslipidemiaPhilip Barter
Heart Research Institute, Camperdown, Sydney, New South Wales, Australia
Am J Cardiol 102:1040-5. 2008..In conclusion, several classes of drugs, including omega-3 fatty acids, can be used in combination with statins to achieve more global improvements in lipid profiles... - Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) studyHerbert Schuster
Humboldt University, Berlin, Germany
Am Heart J 147:705-13. 2004.... - Effect of high-density lipoproteins on the expression of adhesion molecules in endothelial cellsPhilip J Barter
Lipid Research Laboratory, Hanson Institute for Medical Research, Adelaide, Australia
Curr Opin Lipidol 13:285-8. 2002..The mechanism of this potentially anti-atherogenic effect of HDLs remains uncertain, as does its contribution to the cardioprotective effects of HDLs in vivo... - Remodeling of apolipoprotein E-containing spherical reconstituted high density lipoproteins by phospholipid transfer proteinNongnuch Settasatian
Lipid Research Group, Heart Research Institute, Sydney, New South Wales 2050, Australia
J Lipid Res 49:115-26. 2008..It is concluded that apoE enhances the capacity of PLTP to remodel HDL but reduces the ability of HDL to participate in PLTP-mediated phospholipid transfers... - High-density lipoproteins neutralize C-reactive protein proinflammatory activityCarol Wadham
Division of Human Immunology, Hanson Institute, Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia
Circulation 109:2116-22. 2004..CONCLUSIONS: The CRP-induced upregulation of inflammatory adhesion molecules in HUVECs was completely prevented by HDL via their oxidized phospholipid components... - Evidence that phospholipids play a key role in pre-beta apoA-I formation and high-density lipoprotein remodelingKerry Anne Rye
Lipid Research Laboratory, Hanson Institute, Adelaide, South Australia, Australia 5000
Biochemistry 41:12538-45. 2002..In conclusion, these results show that phospholipids play a key role in the CETP-mediated remodeling of rHDL and pre-beta apoA-I formation... - Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatmentGilles Lambert
The Heart Research Institute, Sydney, Australia
Clin Chem 54:1038-45. 2008..Proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes the degradation of the LDL receptor (LDLr) in hepatocytes, and its expression in mouse liver has been shown to decrease with fenofibrate treatment... - Metabolism of apoA-I as lipid-free protein or as component of discoidal and spherical reconstituted HDLs: studies in wild-type and hepatic lipase transgenic rabbitsPatrick Kee
University Department of Medicine, Royal Adelaide Hospital, Adelaide, Australia
Arterioscler Thromb Vasc Biol 22:1912-7. 2002.... - Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosisPhilip J Barter
Hanson Institute and the Department of Cardiology, Royal Adelaide Hospital, Adelaide, Australia
Arterioscler Thromb Vasc Biol 23:160-7. 2003..Thus, it seems important and timely to test the hypothesis in randomized trials of humans that pharmacological inhibition of CETP retards the development of atherosclerosis... - Antiinflammatory actions of HDL: a new insightKerry-Anne Rye
Arterioscler Thromb Vasc Biol 28:1890-1. 2008 - Evidence that hepatic lipase and endothelial lipase have different substrate specificities for high-density lipoprotein phospholipidsMyNgan Duong
Department of Medicine, University of Adelaide, North Terrace, Australia
Biochemistry 42:13778-85. 2003..These results establish that EL and HL have different substrate specificities for rHDL phospholipids and that their interactions with the rHDL surface are regulated by phospholipids... - Formation and metabolism of prebeta-migrating, lipid-poor apolipoprotein A-IKerry Anne Rye
Heart Research Institute, Camperdown, Sydney, NSW, Australia
Arterioscler Thromb Vasc Biol 24:421-8. 2004..This review describes current knowledge regarding the formation, metabolism, and regulation of monomolecular, lipid-free/lipid-poor apoA-I in plasma... - Apolipoprotein A-II inhibits high density lipoprotein remodeling and lipid-poor apolipoprotein A-I formationKerry Anne Rye
Lipid Research Laboratory, Hanson Institute, Adelaide, South Australia 5000, Australia
J Biol Chem 278:22530-6. 2003.... - Low dose apolipoprotein A-I rescues carotid arteries from inflammation in vivoRajesh Puranik
The Heart Research Institute, Lipid Research Group 145, Missenden Road, Sydney, NSW 2050, Australia
Atherosclerosis 196:240-7. 2008..These findings have potential implications for treating acute vascular inflammation in conditions such as acute coronary and stroke syndromes... - Regulation of reconstituted high density lipoprotein structure and remodeling by apolipoprotein EKerry Anne Rye
Lipid Research Group, The Heart Research Institute, Camperdown, Sydney, New South Wales, Australia
J Lipid Res 47:1025-36. 2006.... - High-density lipoproteins as therapeutic targetsStephen J Nicholls
The Heart Research Institute, Sydney, Australia
Curr Opin Lipidol 16:345-9. 2005.... - High-density lipoproteins enhance progenitor-mediated endothelium repair in miceColin Tso
Heart Research Institute, Sydney, NSW 2050, Australia
Arterioscler Thromb Vasc Biol 26:1144-9. 2006..The observation that number is further increased in apoE(-/-) mice after injection of HDL suggests a role for HDL in promoting progenitor-mediated endothelial repair... - Cardioprotective properties of fibrates: which fibrate, which patients, what mechanism?Philip J Barter
Circulation 113:1553-5. 2006 - Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbitsStephen J Nicholls
Heart Research Institute, Sydney, Australia
Circulation 111:1543-50. 2005..CONCLUSIONS: Infusion of rHDL, apoA-I, and phospholipid-SUVs inhibits the early pro-oxidant and proinflammatory changes induced by a periarterial collar in normocholesterolemic rabbits... - Impact of short-term administration of high-density lipoproteins and atorvastatin on atherosclerosis in rabbitsStephen J Nicholls
The Heart Research Institute, Sydney, Australia
Arterioscler Thromb Vasc Biol 25:2416-21. 2005..CONCLUSIONS: Infusing small amounts of HDL rapidly reduces lesion size and is comparable to atorvastatin in promoting a stable plaque phenotype... - Antiinflammatory properties of HDLPhilip J Barter
The Heart Research Institute, 145 Missenden Rd, Camperdown, Sydney 2050, Australia
Circ Res 95:764-72. 2004..These antioxidant and antiinflammatory properties of HDL may be as important as its cholesterol efflux function in terms of protecting against the development of atherosclerosis... - Consumption of saturated fat impairs the anti-inflammatory properties of high-density lipoproteins and endothelial functionStephen J Nicholls
The Heart Research Institute, Sydney, Australia
J Am Coll Cardiol 48:715-20. 2006..In contrast, the anti-inflammatory activity of HDL improves after consumption of polyunsaturated fat. These findings highlight novel mechanisms by which different dietary fatty acids may influence key atherogenic processes... - Homocysteine and cardiovascular disease: is HDL the link?Philip J Barter
Circ Res 99:565-6. 2006 - Apolipoprotein E enhances hepatic lipase-mediated hydrolysis of reconstituted high-density lipoprotein phospholipid and triacylglycerol in an isoform-dependent mannerNeil J Hime
Lipid Research Group, The Heart Research Institute, Camperdown, Sydney, New South Wales, Australia
Biochemistry 43:12306-14. 2004..These results show that apoE increases the rate of HL-mediated phospholipid and triacylglycerol hydrolysis in rHDL and that this influence is isoform dependent... - Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemiaJohn J P Kastelein
Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
N Engl J Med 356:1620-30. 2007..Torcetrapib, an inhibitor of cholesteryl ester transfer protein, may reduce atherosclerotic vascular disease by increasing levels of high-density lipoprotein (HDL) cholesterol... - Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular diseasePhilip J Barter
The Heart Research Institute, Camperdown, Sydney, Australia
J Am Coll Cardiol 47:492-9. 2006..Larger, long-term, randomized, clinical end point trials are required to determine whether the beneficial effects of CETP inhibitors on lipoprotein metabolism can translate into reductions in cardiovascular events... - N-Glycosylation regulates endothelial lipase-mediated phospholipid hydrolysis in apoE- and apoA-I-containing high density lipoproteinsDanielle Skropeta
Lipid Research Group, Heart Research Institute, Camperdown, New South Wales 2050, Australia
J Lipid Res 48:2047-57. 2007..These data show that individual N-linked glycans have unique and important effects on the phospholipase activity and substrate specificity of EL... - Formation of high density lipoproteins containing both apolipoprotein A-I and A-II in the rabbitNeil J Hime
Lipid Research Group, The Heart Research Institute, Camperdown, Sydney, New South Wales 2050, Australia
J Lipid Res 47:115-22. 2006..We conclude that, irrespective of the form in which apoA-II enters the plasma, it is rapidly incorporated into spherical HDLs that also contain apoA-I to form (A-I/A-II)HDL... - Coronary plaque regression: role of low density lipoprotein-apheresisPhilip J Barter
J Am Coll Cardiol 40:228-30. 2002 - Relation between atherogenic dyslipidemia and the Adult Treatment Program-III definition of metabolic syndrome (Genetic Epidemiology of Metabolic Syndrome Project)Diego F Wyszynski
Department of Medicine (Genetics Program, Boston University School of Medicine, Boston, MA, USA
Am J Cardiol 95:194-8. 2005..In subjects aged <35 years, atherogenic dyslipidemia frequently occurs in the absence of other metabolic syndrome risk factors... - Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South AfricaVivienne M Homer
Canterbury Health Laboratories, 8001 Christchurch, New Zealand
Atherosclerosis 196:659-66. 2008..Our study therefore indicates that PCSK9 mediated inhibition of the LDLR does not require PCSK9 autocatalytic cleavage or secretion, suggesting that PCSK9 may also function intracellularly... - Multiple QTLs influencing triglyceride and HDL and total cholesterol levels identified in families with atherogenic dyslipidemiaYi Yu
Department of Medicine (Genetics Program, Boston University School of Medicine, Boston, MA, USA
J Lipid Res 46:2202-13. 2005..These data also indicate that a large proportion of the variance of TG levels in the Turkish population is explained by the interaction of multiple genetic loci...